For instance, patients with lung cancer receiving anti-PD-1 monotherapy demonstrated a higher likelihood of experiencing all-grade TRAEs than those receiving anti-PD-L1 therapy (see Fig. 4). Here, PDCD1 is linked to lung carcinoma.